Peter Schäfer

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Keynote review: Phosphodiesterase-4 as a therapeutic target

Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate <scp>T</scp> cells by inducing degradation of <scp>T</scp> cell repressors <scp>I</scp> karos and <scp>A</scp> iolos via modulation of the <scp>E</scp> 3 ubiquitin ligase complex <scp>CRL</scp> 4 <scp> ^CRBN </scp>

Prolonged Bacterial Culture to Identify Late Periprosthetic Joint Infection: A Promising Strategy

Undertreatment Strongly Decreases Prognosis of Breast Cancer in Elderly Women

Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells

Apremilast mechanism of action and application to psoriasis and psoriatic arthritis

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

The value of synovial biopsy, joint aspiration and C-reactive protein in the diagnosis of late peri-prosthetic infection of total knee replacements